Literature DB >> 23206800

Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration.

Ki Sung Kang1, Noriko Yamabe, Yujing Wen, Masayuki Fukui, Bao Ting Zhu.   

Abstract

Levodopa (L-DOPA) is widely used for symptomatic management in Parkinson's disease. We recently showed that (-)-epigallocatechin-3-gallate, a tea polyphenol, not only inhibits L-DOPA methylation, but also protects against oxidative hippocampal neurodegeneration. In the present study, we sought to determine several other common dietary phenolics, namely, tea catechins [(+)-catechin and (-)-epicatechin] and a representative flavonoid (quercetin), for their ability to modulate L-DOPA methylation and to protect against oxidative hippocampal injury. A combination of in vitro biochemical assays, cell culture-based mechanistic analyses, and in vivo animal models was used. While both tea catechins and quercetin strongly inhibit human liver catechol-O-methyltransferase (COMT)-mediated O-methylation of L-DOPA in vitro, only (+)-catechin exerts a significant inhibition of L-DOPA methylation in both peripheral compartment and striatum in rats. The stronger in vivo effect of (+)-catechin on L-DOPA methylation compared to the other dietary compounds is due to its better bioavailability in vivo. In addition, (+)-catechin strongly reduces glutamate-induced oxidative cytotoxicity in HT22 mouse hippocampal neurons in vitro through inactivation of the nuclear factor-κB signaling pathway. Administration of (+)-catechin also exerts a strong neuroprotective effect in the kainic acid-induced oxidative hippocampal neurodegeneration model in rats. In conclusion, (+)-catechin is a dietary polyphenolic that may have beneficial effects in L-DOPA-based treatment of Parkinson patients by inhibiting L-DOPA methylation plus reducing oxidative neurodegeneration.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23206800      PMCID: PMC3618674          DOI: 10.1016/j.brainres.2012.11.043

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  69 in total

1.  Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration.

Authors:  L C Schmued; K J Hopkins
Journal:  Brain Res       Date:  2000-08-25       Impact factor: 3.252

Review 2.  Progress in Parkinson's disease-where do we stand?

Authors:  André Toulouse; Aideen M Sullivan
Journal:  Prog Neurobiol       Date:  2008-06-05       Impact factor: 11.685

Review 3.  Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors.

Authors:  P T Männistö; S Kaakkola
Journal:  Pharmacol Rev       Date:  1999-12       Impact factor: 25.468

4.  Degeneration of hippocampal CA3 pyramidal cells induced by intraventricular kainic acid.

Authors:  J V Nadler; B W Perry; C Gentry; C W Cotman
Journal:  J Comp Neurol       Date:  1980-07-15       Impact factor: 3.215

5.  Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat.

Authors:  Karen L Eskow Jaunarajs; Kristin B Dupre; Corinne Y Ostock; Thomas Button; Terrence Deak; Christopher Bishop
Journal:  Behav Pharmacol       Date:  2010-10       Impact factor: 2.293

6.  Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers.

Authors:  G Sêdek; K Jorga; M Schmitt; R S Burns; P Leese
Journal:  Clin Neuropharmacol       Date:  1997-12       Impact factor: 1.592

7.  Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis.

Authors:  P Riederer; S Wuketich
Journal:  J Neural Transm       Date:  1976       Impact factor: 3.575

8.  Phytochemicals inhibit catechol-O-methyltransferase activity in cytosolic fractions from healthy human mammary tissues: implications for catechol estrogen-induced DNA damage.

Authors:  Majorie B M van Duursen; J Thomas Sanderson; Paul C de Jong; Marlies Kraaij; Martin van den Berg
Journal:  Toxicol Sci       Date:  2004-07-14       Impact factor: 4.849

9.  Kainic acid-induced activation of nuclear factor-kappaB in rat hippocampus.

Authors:  Y Matsuoka; Y Kitamura; M Okazaki; K Terai; T Taniguchi
Journal:  Exp Brain Res       Date:  1999-01       Impact factor: 1.972

10.  Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference.

Authors:  Thomas Müller
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more
  10 in total

Review 1.  Therapeutic perspectives of epigenetically active nutrients.

Authors:  M Remely; L Lovrecic; A L de la Garza; L Migliore; B Peterlin; F I Milagro; A J Martinez; A G Haslberger
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

2.  Protection against glutathione depletion-associated oxidative neuronal death by neurotransmitters norepinephrine and dopamine: Protein disulfide isomerase as a mechanistic target for neuroprotection.

Authors:  Hye Joung Choi; Tong-Xiang Chen; Ming-Jie Hou; Ji Hoon Song; Peng Li; Chun-Feng Liu; Pan Wang; Bao Ting Zhu
Journal:  Acta Pharmacol Sin       Date:  2022-03-28       Impact factor: 7.169

3.  Behavioral and neurochemical effects of alpha-lipoic Acid in the model of Parkinson's disease induced by unilateral stereotaxic injection of 6-ohda in rat.

Authors:  Dayane Pessoa de Araújo; Caren Nádia Soares De Sousa; Paulo Victor Pontes Araújo; Carlos Eduardo de Souza Menezes; Francisca Taciana Sousa Rodrigues; Sarah Souza Escudeiro; Nicole Brito Cortez Lima; Manoel Claúdio Azevedo Patrocínio; Lissiana Magna Vasconcelos Aguiar; Glauce Socorro de Barros Viana; Silvânia Maria Mendes Vasconcelos
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-19       Impact factor: 2.629

4.  Ampelopsis Radix Protects Dopaminergic Neurons against 1-Methyl-4-phenylpyridinium/1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Toxicity in Parkinson's Disease Models In Vitro and In Vivo.

Authors:  Hanbyeol Park; Jin Sup Shim; Hyo Geun Kim; Hyejung Lee; Myung Sook Oh
Journal:  Evid Based Complement Alternat Med       Date:  2013-09-24       Impact factor: 2.629

5.  The Designer Drug 3-Fluoromethcathinone Induces Oxidative Stress and Activates Autophagy in HT22 Neuronal Cells.

Authors:  Kamila Siedlecka-Kroplewska; Agata Wrońska; Grzegorz Stasiłojć; Zbigniew Kmieć
Journal:  Neurotox Res       Date:  2018-04-14       Impact factor: 3.911

6.  12/15-Lipoxygenase Regulation of Diabetic Cognitive Dysfunction Is Determined by Interfering with Inflammation and Cell Apoptosis.

Authors:  Qi Chen; Qixue Zheng; Yang Yang; Ying Luo; Hong Wang; Huan Li; Lu Yang; Congli Hu; Jiahua Zhang; Yuke Li; Hui Xia; Zhihao Chen; Jie Ma; Xiaoyan Tian; Junqing Yang
Journal:  Int J Mol Sci       Date:  2022-08-12       Impact factor: 6.208

Review 7.  Recent trends in the development of nanophytobioactive compounds and delivery systems for their possible role in reducing oxidative stress in Parkinson's disease models.

Authors:  Palanivel Ganesan; Hyun-Myung Ko; In-Su Kim; Dong-Kug Choi
Journal:  Int J Nanomedicine       Date:  2015-10-29

8.  Quercetin ameliorates Aβ toxicity in Drosophila AD model by modulating cell cycle-related protein expression.

Authors:  Yan Kong; Ke Li; Tingting Fu; Chao Wan; Dongdong Zhang; Hang Song; Yao Zhang; Na Liu; Zhenji Gan; Liudi Yuan
Journal:  Oncotarget       Date:  2016-10-18

Review 9.  Neuroprotective Polyphenols: A Modulatory Action on Neurotransmitter Pathways.

Authors:  Elzbieta Rebas; Jowita Rzajew; Tomasz Radzik; Ludmila Zylinska
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

10.  Comparison of the Metabolic Profiles in the Plasma and Urine Samples Between Autistic and Typically Developing Boys: A Preliminary Study.

Authors:  Xin-Jie Xu; Xiao-E Cai; Fan-Chao Meng; Tian-Jia Song; Xiao-Xi Wang; Yi-Zhen Wei; Fu-Jun Zhai; Bo Long; Jun Wang; Xin You; Rong Zhang
Journal:  Front Psychiatry       Date:  2021-06-04       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.